echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Latest Medical News > Huadong Medicine awarded South Korean company Daewon company oral small molecule GLP-1R agonist development rights

    Huadong Medicine awarded South Korean company Daewon company oral small molecule GLP-1R agonist development rights

    • Last Update: 2021-10-10
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    On September 29, Huadong Pharmaceutical announced that its wholly-owned subsidiary Hangzhou Sino-American Huadong Pharmaceutical Co.


    TTP273 is an oral small molecule non-peptide GLP-1 receptor agonist for the treatment of type 2 diabetes


    According to the agreement, Huadong Medicine will receive a down payment of US$1.


    Huadong Medicine is currently conducting Phase 2 clinical trials of TTP273 in China and Taiwan


    Huadong Medicine and Daewon will jointly establish a joint steering committee.


    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.